Nephrology – Medxy AI

Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients

By MedXY 10/20/2025

This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly patients.

Nephrology Neurology news

Assessing the Role of Kidney Function in Alzheimer’s Disease Blood Biomarker Interpretation and Amyloid-β Positivity Prediction

By MedXY 10/20/2025

Kidney function influences certain Alzheimer's disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD diagnosis regardless of renal status.

Cardiology Nephrology news

Integrating Triglyceride-Glucose Indices with Obesity Measures Enhances Cardiovascular and Mortality Risk Prediction in CKM Syndrome

By MedXY 10/19/2025

This study demonstrates that triglyceride-glucose-related indices combined with obesity measures significantly predict cardiovascular outcomes and mortality in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3, offering improved prognostic utility.

Cardiology Diabetes & Endocrinology Nephrology news

Insulin Resistance Indices as Predictors of Cardio-Renal-Metabolic Multimorbidity: Insights from the UK Biobank

By MedXY 10/19/2025

This study demonstrates that insulin resistance indices, particularly TyG-WC, TyG-WHtR, and METS-IR, robustly predict the risk and progression of cardio-renal-metabolic multimorbidity, with inflammation and kidney function mediating these associations.

Diabetes & Endocrinology Nephrology Specialties

Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort

By MedXY 10/19/2025

This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.

Nephrology news Oncology

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY 10/16/2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Cardiology Nephrology news

Enhancing Cardiovascular Health in Kidney Transplant Recipients: Updated Evidence on Physical Activity Interventions

By MedXY 10/12/2025

An updated meta-analysis of 23 RCTs reveals that physical activity improves cardiorespiratory fitness and HDL cholesterol in adult kidney transplant recipients, suggesting important cardiovascular benefits despite current study limitations.

Cardiology Nephrology news

Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis

By MedXY 10/11/2025

Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.

Cardiology Nephrology news

Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes

By MedXY 10/11/2025

A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.

Allergy & Immunology Nephrology

Oral Iptacopan Shows Promise in Reducing Proteinuria in C3 Glomerulopathy: Results from a Global Phase 3 Trial

By MedXY 10/10/2025

The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation.

Critical Care Nephrology news

Evaluating Cost-Effectiveness of Accelerated Versus Standard Initiation of Renal Replacement Therapy in Severe Acute Kidney Injury

By MedXY 10/05/2025

This analysis reveals that standard initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI) offers greater quality-adjusted life years (QALYs) at an acceptable increased cost, suggesting cost-effectiveness in Canadian healthcare settings.

Cardiology Clinical Updates Nephrology news Specialties

Sustained Cardiovascular Health in Young Adulthood Significantly Reduces Midlife Cardiovascular and Kidney Risks

By MedXY 10/01/2025

A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.

Cardiology Clinical Updates Nephrology

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY 09/27/2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall major cardiovascular events.

Cardiology Nephrology

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY 09/27/2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise for those with chronic kidney disease.

Clinical Updates Nephrology news

Lubiprostone Therapy in Chronic Kidney Disease: A Phase 2 Trial Reveals Mitochondrial Enhancement via Polyamine Modulation

By MedXY 09/19/2025

A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic avenue.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Flexovital Food Supplement Shows Promise in Mitigating Cardiovascular-Kidney-Metabolic Syndrome in Preclinical Model

By MedXY 08/30/2025

Flexovital, a nitric oxide-enhancing supplement, effectively attenuates metabolic, cardiovascular, and renal dysfunctions in a mouse model of cardiovascular-kidney-metabolic syndrome induced by unilateral nephrectomy and Western diet.

Clinical Updates Nephrology Specialties

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

By MedXY 08/27/2025

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone's efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future directions for mineralocorticoid receptor antagonism in this population.

Nephrology Specialties

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis

By MedXY 08/27/2025

The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this population.

Nephrology news Specialties

Silent Threats: Why Uremia is Affecting Younger Adults and How to Protect Your Kidneys

By MedXY 08/27/2025

Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prevention strategies.